Biofrontera AG, which specializes in the treatment of sun-induced skin cancer, has appointmented Jeffrey Holm as Vice President of Marketing, to further strengthen its US commercialization activities. Mr. Holm will be responsible for developing innovative marketing strategies to drive support of the Company’s combination of the topical prescription drug Ameluz® and the medical device BF-RhodoLED® for the photodynamic therapy (PDT) treatment of skin cancer precursors, as well as bolster company communications with US dermatologists. 

Mr. Holm is a veteran of the dermatology market with more than 35 years of experience in sales and marketing and a thorough understanding of the legal requirements in the US healthcare system. He was most recently Executive Director for Sales and Marketing at Taro Pharmaceuticals Inc., where he led a 64-person marketing and sales team. Prior to that, he spent 18 years at Ferndale Healthcare Inc., where he held several senior roles including Chief Operating Officer and Vice President, Sales & Marketing. Jeffrey began his career at Allergan and holds a BA in Journalism from Texas Christian University.